Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Nicolas Duployez, Alice Marceau‐Renaut, Nicolas Boissel, et al.
Blood (2016) Vol. 127, Iss. 20, pp. 2451-2459
Open Access | Times Cited: 218

Showing 1-25 of 218 citing articles:

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu H. Estey, David Grimwade, et al.
Blood (2016) Vol. 129, Iss. 4, pp. 424-447
Open Access | Times Cited: 5146
Acute myeloid leukemia: 2019 update on risk‐stratification and management
Elihu H. Estey
American Journal of Hematology (2018) Vol. 93, Iss. 10, pp. 1267-1291
Open Access | Times Cited: 332
The genomic landscape of core-binding factor acute myeloid leukemias
Zachary Faber, Xiang Chen, Amanda Larson Gedman, et al.
Nature Genetics (2016) Vol. 48, Iss. 12, pp. 1551-1556
Open Access | Times Cited: 250
Diagnosis and classification of hematologic malignancies on the basis of genetics
Justin Taylor, Wenbin Xiao, Omar Abdel‐Wahab
Blood (2017) Vol. 130, Iss. 4, pp. 410-423
Open Access | Times Cited: 212
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi, Naomi Kawashima, Yuichi Ishikawa
Cancer Science (2019) Vol. 111, Iss. 2, pp. 312-322
Open Access | Times Cited: 211
[Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
Jun Wu, Airu Lu, L P Zhang, et al.
PubMed (2019) Vol. 40, Iss. 1, pp. 52-57
Closed Access | Times Cited: 192
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
Friederike Christen, Kaja Hoyer, Kenichi Yoshida, et al.
Blood (2019) Vol. 133, Iss. 10, pp. 1140-1151
Open Access | Times Cited: 121
Engaging chromatin: PRC2 structure meets function
Paul Chammas, Ivano Mocavini, Luciano Di Croce
British Journal of Cancer (2019) Vol. 122, Iss. 3, pp. 315-328
Open Access | Times Cited: 110
Acute Myeloid Leukemia: The Good, the Bad, and the Ugly
Andrew Kuykendall, Nicolas Duployez, Nicolas Boissel, et al.
American Society of Clinical Oncology Educational Book (2018), Iss. 38, pp. 555-573
Closed Access | Times Cited: 101
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Frank G. Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
Blood (2019) Vol. 134, Iss. 19, pp. 1608-1618
Open Access | Times Cited: 101
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
Peter Paschka, Richard F. Schlenk, Daniela Weber, et al.
Leukemia (2018) Vol. 32, Iss. 7, pp. 1621-1630
Closed Access | Times Cited: 97
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
A-K Eisfeld, Krzysztof Mrózek, Jessica Kohlschmidt, et al.
Leukemia (2017) Vol. 31, Iss. 10, pp. 2211-2218
Open Access | Times Cited: 90
An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
Sayer Al-harbi, Mahmoud Aljurf, Mohamad Mohty, et al.
Blood Advances (2020) Vol. 4, Iss. 1, pp. 229-238
Open Access | Times Cited: 87
Cohesin subunit RAD21: From biology to disease
Haizi Cheng, Nenggang Zhang, Debananda Pati
Gene (2020) Vol. 758, pp. 144966-144966
Open Access | Times Cited: 87
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, et al.
Blood Advances (2020) Vol. 4, Iss. 1, pp. 66-75
Open Access | Times Cited: 85
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Gautam Borthakur, Hagop M. Kantarjian
Blood Cancer Journal (2021) Vol. 11, Iss. 6
Open Access | Times Cited: 76
Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge
Julie Quessada, Wendy Cuccuini, Paul Saultier, et al.
Genes (2021) Vol. 12, Iss. 6, pp. 924-924
Open Access | Times Cited: 76
Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia
Shunjie Yu, Sen Yang, Lijuan Hu, et al.
Annals of Hematology (2025)
Open Access | Times Cited: 1
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia
John P. Leonard, Peter Martin, Gail J. Roboz
Journal of Clinical Oncology (2017) Vol. 35, Iss. 23, pp. 2708-2715
Closed Access | Times Cited: 77
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication
Nikolaus Jahn, Tobias Terzer, Eric Sträng, et al.
Blood Advances (2020) Vol. 4, Iss. 24, pp. 6342-6352
Open Access | Times Cited: 64
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
Jean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 63
Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
Michael Leisch, Bettina Jansko, Nadja Zaborsky, et al.
Cancers (2019) Vol. 11, Iss. 2, pp. 252-252
Open Access | Times Cited: 63
The clinical mutatome of core binding factor leukemia
Sabrina Opatz, Stefanos A. Bamopoulos, Klaus H. Metzeler, et al.
Leukemia (2020) Vol. 34, Iss. 6, pp. 1553-1562
Open Access | Times Cited: 62
The Role of Additional Sex Combs-Like Proteins in Cancer
Jean‐Baptiste Micol, Omar Abdel‐Wahab
Cold Spring Harbor Perspectives in Medicine (2016) Vol. 6, Iss. 10, pp. a026526-a026526
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top